In most non-AML cancer cells, including other hematopoietic cancer cells, IRF8 deletion is associated with a positive score, indicating that IRF8 deletion leads to an increased cell proliferation of the cells (Figure 2D). This evidence concerns the gene IRF8 and hematopoietic and lymphoid cell neoplasm.